Skip to main content
. 2023 Jan 6;9(1):eade1694. doi: 10.1126/sciadv.ade1694

Fig. 6. CDC25/CDK2 and calcineurin modify toxicity in motor neuron–derived cells modeling SBMA.

Fig. 6.

(A) MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] cell viability assays in MN1 cells stably expressing AR24Q or AR100Q and treated with DHT (10 μM, 48 hours), together with vehicle or sanguinarine chloride (0.1 μM, 16 hours), NSC-663284 (1 μM, 16 hours), or gossypol (10 μM, 16 hours) (n = 3 to 6 biological replicates). (B) MTT cell viability assay in MN1 cells stably expressing AR100Q or AR100Q-S96A treated with sanguinarine chloride or NSC-663284 or transfected with empty vector (mock) or vector expressing CDC25 and treated with DHT (10 μM, 48 hours) (n = 3 to 9 biological replicates). (C) MTT cell viability assay in MN1 cells stably expressing AR100Q or AR100Q-S96D treated with DHT (10 μM, 48 hours), together with FK506 (16 hours) or cyclosporin A (CSA, 16 hours) at the indicated dosages (n = 4 to 6 biological replicates). Graphs show means ± SEM, two-way ANOVA followed by Tukey HSD tests.